Robert Fenstermaker
Roswell Park Dept of Neurosurgery · Chief Medical Officer · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Fenstermaker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05363826 · Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC · unknown · Glioblastoma Multiforme of Brain, Glioma, Sarcomatous · principal investigator
- Ph2NCT05163080 · SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)MimiVax, LLC · unknown · Newly Diagnosed Glioblastoma · principal investigator
- Ph2NCT02455557 · SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaRoswell Park Cancer Institute · active not recruiting · Glioblastoma, Gliosarcoma · principal investigator
- Ph1NCT01250470 · Vaccine Therapy and Sargramostim in Treating Patients With Malignant GliomaRoswell Park Cancer Institute · completed · Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Immunotherapy for gliomas with monoclonal antibodies targeting MCSPR21NS054167 · NINDS · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2006 to 2007 · $230,024 awarded in 2007Same name and institution; not confirmed by an ID
- Targeting the anti-apoptotic protein survivin in gliomaR21NS049309 · NINDS · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2004 to 2005 · $225,181 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Treatment of Glioblastoma: the combination of fluorescence guided surgery and photodynamic therapyR44CA247127 · NCI · PHOTOLITEC, LLC · PI WILLIAM R POTTER · fiscal years 2020 to 2022Named on NCT05363826
- Administrative CoreP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dale Henry · fiscal years 2008 to 2026Named on NCT01250470
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:40 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer Immunol Immunother · 2016148 citationsRCR 4.6
- Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.J Clin Oncol · 2023148 citationsRCR 13.7
- CT-assisted percutaneous anterior cordotomy: technical note.Surg Neurol · 199511 citationsRCR 0.7
- Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.Cancer Immunol Immunother · 20253 citationsRCR 0.8